Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$3.53
+0.6%
$3.52
$3.96
$12.00
$6.33M1.557,305 shs3,195 shs
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
$1.11
-1.7%
$1.24
$0.85
$4.40
$35.75M0.2131,100 shs8,044 shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$3.40
+13.3%
$4.60
$1.04
$7.25
$50.87M-0.39872,647 shs273,000 shs
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
$8.16
$8.04
$0.83
$8.35
$564.92M0.35998,827 shsN/A
Soligenix Inc. stock logo
SNGX
Soligenix
$1.36
+7.1%
$1.71
$1.09
$7.61
$4.44M1.87350,702 shs259,106 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00%+3.52%-2.35%+23.92%-44.13%
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
0.00%-4.18%-4.98%+1.59%-67.69%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00%-4.76%-42.75%-28.40%+101.34%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
0.00%0.00%+0.62%+327.23%+377.19%
Soligenix Inc. stock logo
SNGX
Soligenix
0.00%+5.83%-29.44%-35.20%-82.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/AN/AN/AN/A
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
0.8729 of 5 stars
0.03.00.00.01.93.30.0
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.8891 of 5 stars
0.05.00.00.01.61.70.0
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
1.6549 of 5 stars
2.15.00.00.00.63.30.0
Soligenix Inc. stock logo
SNGX
Soligenix
1.0023 of 5 stars
0.03.00.00.03.10.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.00
N/AN/AN/A
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
0.00
N/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00
N/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
2.29
Hold$8.504.17% Upside
Soligenix Inc. stock logo
SNGX
Soligenix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AEZS, RGLS, CPIX, AKTX, and SNGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$9.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$7.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$28.00 ➝ $11.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$8.00 ➝ $7.00
(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
$2.37M2.67N/AN/A$14.99 per share0.24
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/A$0.84 per shareN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$41.08M1.24$0.29 per share11.66$1.61 per share2.11
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/A$1.17 per shareN/A
Soligenix Inc. stock logo
SNGX
Soligenix
-$117.03K-37.93N/AN/A$1.64 per share0.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
-$16.55M-$14.86N/AN/A-760.32%-83.45%-45.76%8/11/2025 (Estimated)
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
-$19.79MN/A0.00N/AN/A-213.59%-65.60%8/18/2025 (Estimated)
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$6.48M-$0.25N/AN/A-7.98%6.92%2.33%8/5/2025 (Estimated)
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%8/6/2025 (Estimated)
Soligenix Inc. stock logo
SNGX
Soligenix
-$8.27M-$4.29N/AN/AN/AN/A-223.89%-103.50%8/8/2025 (Estimated)

Latest AEZS, RGLS, CPIX, AKTX, and SNGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Soligenix Inc. stock logo
SNGX
Soligenix
-$0.79N/AN/AN/AN/AN/A
5/9/2025Q1 2025
Soligenix Inc. stock logo
SNGX
Soligenix
-$0.67-$1.06-$0.39-$1.06N/AN/A
5/8/2025Q1 2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.29-$0.15+$0.14-$0.15N/AN/A
5/6/2025Q1 2025
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/A$0.15N/A$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/AN/AN/AN/AN/A
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/AN/A
Soligenix Inc. stock logo
SNGX
Soligenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
N/A
5.94
5.93
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/A
0.16
0.16
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.18
1.25
1.09
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/A
16.31
16.31
Soligenix Inc. stock logo
SNGX
Soligenix
N/A
1.85
1.85

Institutional Ownership

CompanyInstitutional Ownership
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
0.73%
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
5.06%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
15.51%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
92.38%
Soligenix Inc. stock logo
SNGX
Soligenix
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aeterna Zentaris Inc. stock logo
AEZS
Aeterna Zentaris
201.79 million1.79 millionNo Data
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
932.18 million19.92 millionNot Optionable
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
8014.96 million8.25 millionOptionable
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
3069.23 million66.22 millionOptionable
Soligenix Inc. stock logo
SNGX
Soligenix
203.26 million3.16 millionNot Optionable

Recent News About These Companies

SNGX: Multiple Catalysts Upcoming in 2H25…

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aeterna Zentaris stock logo

Aeterna Zentaris NASDAQ:AEZS

$3.53 +0.02 (+0.57%)
As of 07/11/2025

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Akari Therapeutics stock logo

Akari Therapeutics NASDAQ:AKTX

$1.11 -0.02 (-1.74%)
As of 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Cumberland Pharmaceuticals stock logo

Cumberland Pharmaceuticals NASDAQ:CPIX

$3.40 +0.40 (+13.33%)
Closing price 04:00 PM Eastern
Extended Trading
$3.50 +0.10 (+3.06%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Regulus Therapeutics stock logo

Regulus Therapeutics NASDAQ:RGLS

$8.16 0.00 (0.00%)
As of 06/25/2025

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Soligenix stock logo

Soligenix NASDAQ:SNGX

$1.36 +0.09 (+7.09%)
Closing price 04:00 PM Eastern
Extended Trading
$1.34 -0.02 (-1.47%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.